Skip to content

Study · Observational study · n = 325 · 2015

2 results

Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.

Peltier A, Aoun F, De Ruyter V, Cabri P, Van Velthoven R

Prostate cancer28 Jan 2015Cited by 11 (Europe PMC)

PMID25694830 (opens in a new tab)PMCIDPMC4324912 (opens in a new tab)DOI10.1155/2015/978194 (opens in a new tab)PepBankPUB-25694830
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy and its effects on LUTS were evaluated focusing on symptom relief and changes in quality of life (QOL) related to urinary symptoms (November 2006 to May 2010). Inclusion criteria were age >18 years, histologically confirmed advanced or metastatic prostate cancer, and life expectancy ≥12 months. Exclusion criteria were treatment with any LHRH analogue within the last 6 months or any other investigational agent within the last 3 months before study entry. Patients who received one or more triptorelin doses and had one or more efficacy assessments were evaluated. In total, 325 patients were included with a median age of 74 years (50 to 95 years). Mean age at first diagnosis was 73 ± 8 years. Moderate (IPSS 8-19) to severe (IPSS ≥ 20) LUTS were observed in 62% of patients. Triptorelin reduced LUTS severity. This improvement was perceived within the first 24 weeks of treatment and was maintained after 48 weeks. A decrease in PSA level was also observed.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In advanced prostate cancer patients, triptorelin treatment was associated with reduced urinary symptom severity within 24 weeks, maintained after 48 weeks.

    In plain wordsIn prostate cancer patients, triptorelin treatment was linked to reduced urinary symptoms within 24 weeks, maintained after 48 weeks.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseLower urinary tract symptom severity
    Study

    n = 325

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Triptorelin reduced LUTS severity. This improvement was perceived within the first 24 weeks of treatment and was maintained after 48 weeks.
    1 context sentence
    Summary · context
    This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy
  2. 02HumanObservational studyEfficacy outcome

    In advanced prostate cancer patients, triptorelin treatment was associated with decreased PSA levels.

    In plain wordsIn prostate cancer patients, triptorelin treatment was linked to lower PSA levels.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePSA level
    Study

    n = 325

    Outcome group
    Endogenous peptide levels · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A decrease in PSA level was also observed.
    1 context sentence
    Summary · context
    This prospective, noninterventional, open-label, multicentre, Belgian study assessed the prevalence of moderate to severe lower urinary tract symptoms (LUTS) in patients with locally advanced or metastatic prostate cancer scheduled to receive triptorelin therapy

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.